Welcome To Weekend Reading
Greetings, hope everyone is enjoying a lovely Saturday. Before heading out to plant a seed, yes one seed that was given to Nana by the little people, I wanted to add a few June updates for your reading pleasure this weekend.
In this issue of "Weekend Reading" I suggest a new learning activity, as well as some great articles written by a small group of dedicated bloggers who share their personal stories about living with and treating HCV.
We begin with this awesome video presentation; "Eliminating the HCV Scourge: Together We Can Do It," released last month over at ViralEd.
Sit back and watch HCV experts Nezam H. Afdhal, MD and Mark Sulkowski, MD discuss the most critical aspects of HCV prevention, management and treatment, here are a few highlights to get you started;
Treating HCV: patients with diabetes & obesity
Treating HCV genotype 4
Treating HCV: intravenous drugs users
Launch the on-demand program, here.
In Case You Missed It
Nezam H. Afdhal, MD
25 Years From Discovery To Cure: The Hepatitis C Story
Dr. Afdhal discusses how discovery of the virus lead to understanding the global epidemiology and modes of spread of hepatitis C and the recognition that it was the commonest cause of cirrhosis, liver cancer and need for liver transplantation.
Begin, here....
Regimens for treating genotype 2, 3, 4, 5, or 6 HCV infection
New At Clinical Care Options
Non–Genotype 1 HCV Now and in the Near Future
Posted June 9
In this downloadable slideset, Jordan J. Feld, MD, MPH, and Andrew J. Muir, MD, review current and emerging regimens for treating patients with genotype 2, 3, 4, 5, or 6 HCV infection.
** Free registration required
Special NVHR Conference Call: A National Strategy for the Elimination of Hepatitis B & C
This call was held on Monday, May 16, 2016 at 2 pm Eastern. It has been archived, to access the slides, please click here. Publication Updates Around The Web
June Issue of HCV Next
Fighting the War on HCV Within the Veterans Health Administration System
Fighting the War on HCV Within the Veterans Health Administration System
Other Highlights
Our Call to Arms: HCV Kills More Than Any Other Infectious Disease
Q & A: Treating People Who Inject Drugs
HCV Treatments Increase Amount of Spared Livers for Transplantation
Ledipasvir/Sofosbuvir Leads to High Real-World SVR in HIV/HCV Coinfection
AGATE-I: '3-D Regimen' Plus Ribavirin Yields High Response in Genotype 4 HCV
DAA Non-Adherence Results in Lower Virologic Response Rates
Chronic Liver Disease Represents 'Excessive Burden' for Individuals, Health Care System
FDA Issues Recommendations for Development of DAAs for HCV
CDC: More People Die of HCV Than any Other Infectious Disease
Our Call to Arms: HCV Kills More Than Any Other Infectious Disease
Q & A: Treating People Who Inject Drugs
HCV Treatments Increase Amount of Spared Livers for Transplantation
Ledipasvir/Sofosbuvir Leads to High Real-World SVR in HIV/HCV Coinfection
AGATE-I: '3-D Regimen' Plus Ribavirin Yields High Response in Genotype 4 HCV
DAA Non-Adherence Results in Lower Virologic Response Rates
Chronic Liver Disease Represents 'Excessive Burden' for Individuals, Health Care System
FDA Issues Recommendations for Development of DAAs for HCV
CDC: More People Die of HCV Than any Other Infectious Disease
HCV Advocate Monthly Pipeline Update
Each month HCV Advocate presents an update on the HCV Pipeline written by Alan Franciscus. Review study results with commentary from the following pharmaceutical companies that make hepatitis C medications; AbbVie, Gilead, Janssen (Achillion/Alios), Merck and Regulus. A note from Alan Franciscus
Within this section, I will list the genotype(s) being studied and the phase of the study with a brief recap of the study . You will note that many of the drugs or combinations of drugs are pan-genotypic—that is they work on many or most of the HCV genotypes . Many of the drugs listed have been updated with the latest information from the Liver Meeting 2015 and the International Liver Congress 2016 .
Begin, here..
Just So You Know
The HCV Advocate produces two monthly newsletters;
HCV Advocate is posted on the first of the month and the Mid-Month Edition is published on the 15th of the month.
HCV Advocate is posted on the first of the month and the Mid-Month Edition is published on the 15th of the month.
The Monthly HCV Advocate: Monthly columns include “HealthWise,” written by Lucinda Porter, RN, “What’s New,” written by Alan Franciscus, and “Snapshots,” written by Alan Franciscus.
The Mid-Month Edition: Monthly columns include “Snapshots” by Alan Franciscus, “What’s New” by Alan Franciscus, and updates of our HCV drug pipeline.
Monthly Publications:
Hepatitis C Newsletters
On this blog each month an index of HCV Newsletters is posted with noteworthy updates from around the web.
Blog Updates
With direct acting antivirals approved for all Australians with hepatitis C, regardless of severity of damage, the figures are looking good!
June 10, 2016 • By Grace Campbell
It's very exciting to be part of this first wave of successful treatment. I didn't think I could imagine Australia free of hepatitis C, but maybe it's a possibility. We can but hope.
Of Interest
June 6
#3LiverTransplants: First Recovery (Part 1)
June 9, 2016 • By Colton Cooper Colton Cooper shares his inspirational story about his third liver transplant
Although I had a fresh ten-inch scar across my chest, multiple IV lines running through my veins, taking a ton of medicines that I can’t pronounce and stuck lying in a hospital bed, I felt healthier than I had been in a very long time.
Begin, here...
Reducing Medical Costs
By Lucinda K. Porter, RN - June 9, 2016
By Lucinda K. Porter, RN - June 9, 2016
I am insured though the Affordable Care Act (ACA), also known as Obamacare. Before ACA, I was uninsurable because of hepatitis C. However, the Health Insurance Portability and Accountability Act (HIPAA) allowed me to keep my insurance plan when I left Stanford Medical Center.
The Quiet Creeping of Corruption
June 9, 2016 • By Greg Jefferys
It looks likely that in 2016 generic Hepatitis C medicines will reduce Gilead's profits by a few billion dollars. In the scheme of things, for a company that makes tens of billions of dollars profit each year it is not a big thing but for greedy people and greedy, rapacious corporations, every dollar counts.
Hepatitis C, Asparagus and Tending Our Gardens With Meditation
June 7, 2016 • By Matt Starr
I meditate to settle into myself, to heal my overly busy mind and body from the ravages of liver disease. Sitting with awareness only on the breath, you can discover health of mind, body, and spirit.
When the Pain Won’t Go Away
June 6, 2016 • By Kimberly Morgan Bossley
My movement throughout my house is slower as the hardwood floors under my feet cause me to be overly cautious with my steps. Throughout my journey with hep C, I have lost feeling in my feet. Sure I have nerve pain, but there is a numbness that warrants me to insure each step is planted firmly.
By Karen Hoyt - June 9, 2016
When you get diagnosed with hep C, you don’t know a lot about what’s going on. Sure, you get on websites like this one and try to get some information – (loud...
By Jenelle Marie Davis - June 9, 2016
What does the liver do? The liver’s primary purpose is to clean the blood. Blood needs to be cleaned both because the body naturally produces some toxins and because some of the...
What does the liver do? The liver’s primary purpose is to clean the blood. Blood needs to be cleaned both because the body naturally produces some toxins and because some of the...
Strategy: Next treatment
By Rick Nash - June 8, 2016
How it helps combat the treatment: When the first treatment failed there wasn’t anything in the near future. But there is always hope, at the time medical advances in genomics were finding...
How it helps combat the treatment: When the first treatment failed there wasn’t anything in the near future. But there is always hope, at the time medical advances in genomics were finding...
One in Three People Worldwide Has Had Hepatitis B, So Why Do We Feel So Alone?
By Christine Kukka - June 8
Hepatitis B is the global pandemic no one talks about, yet one in three people worldwide has been infected. In 2013, hepatitis B and C together was the seventh-leading cause of death worldwide, with hepatitis B causing 780,000 deaths annually.
Begin, here..
Hepatitis B is the global pandemic no one talks about, yet one in three people worldwide has been infected. In 2013, hepatitis B and C together was the seventh-leading cause of death worldwide, with hepatitis B causing 780,000 deaths annually.
Begin, here..
Gastroenterology Special Issue on Alcoholic vs Non-Alcoholic Fatty Liver Disease
By Dr. Kristine Novak - June 9
A special issue of Gastroenterology is devoted to comparing alcoholic vs nonalcoholic fatty liver disease. In an introduction to the issue, Arun Sanyal et al write that alcoholic liver disease (ALD) and nonalcoholic fatty liver disease (NAFLD) have much in common, including histologic features and activation of pathways involved in their pathogenesis.
By Dr. Kristine Novak - June 9
A special issue of Gastroenterology is devoted to comparing alcoholic vs nonalcoholic fatty liver disease. In an introduction to the issue, Arun Sanyal et al write that alcoholic liver disease (ALD) and nonalcoholic fatty liver disease (NAFLD) have much in common, including histologic features and activation of pathways involved in their pathogenesis.
Begin, here..
Published on Jun 9, 2016
Boise Dr. Magni Hamso with Terry Reilly Health Services talks about hepatitis C
Related
Idaho forced to ration costly hepatitis C cure
By Cynthia Sewell
June 11
Limited funds and high demand have forced many states to restrict coverage to those patients with the most severe liver scarring, called fibrosis.
“I certainly sympathize with the people who have to create these thresholds or these qualifications for treatment,” Box said. “I do not think anybody is withholding therapy out of any other motive than they are in charge of a budget, and these are budget-busting costs.”
Hepatitis C patients also draw limited sympathy because of the self-inflicted nature of the disease. That means treatment costs draw more resistance than, say, the cost of treating cancer, Box said.
Begin, here....
2,436 patients with hepatitis C in one Alabama ER since implementing widespread testing in 2013
Hepatitis C testing in the emergency department at the University of Alabama at Birmingham Hospital has discovered 2,436 positive cases since testing began in September 2013.
Begin, here..Have a safe weekend.
Tina
No comments:
Post a Comment